Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,533Revenue $M0.3Net Margin (%)-79,308.5Altman Z-Score3.8
Enterprise Value $M1,424EPS $-6.4Operating Margin %-74,461.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-79,308.5Higher ROA y-yY
Price/Book17.610-y EBITDA Growth Rate %--Quick Ratio5.0Cash flow > EarningsY
Price/Sales4,7565-y EBITDA Growth Rate %--Current Ratio5.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-78.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-151.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M40.3ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TSRODavid Swensen 2015-12-31 Sold Out -0.08%$40.35 - $52.91
($47.98)
$ 38.05-21%Sold Out0
TSRODavid Swensen 2015-09-30 Buy 0.08%$38.97 - $65.8
($54.68)
$ 38.05-30%New holding6,238
TSROLeon Cooperman 2015-06-30 Sold Out -0.05%$50.84 - $64.65
($57.38)
$ 38.05-34%Sold Out0
TSROLeon Cooperman 2015-03-31 Buy 0.05%$36.62 - $61.41
($47.12)
$ 38.05-19%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.1913.84view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.1913.84view
SANDELL SCOTT D10% Owner 2016-03-18Buy1,420,858$35.1913.84view
MOTT DAVID MDirector, 10% Owner 2016-03-18Buy1,420,858$35.1913.84view
KERINS PATRICK J10% Owner 2016-03-18Buy710,429$35.1913.84view
BASKETT FOREST10% Owner 2016-03-18Buy1,420,858$35.1913.84view
BARRIS PETER J10% Owner 2016-03-18Buy1,420,858$35.1913.84view
BARRETT M JAMES10% Owner 2016-03-18Buy710,429$35.1913.84view
NEW ENTERPRISE ASSOCIATES 13 L10% Owner 2016-03-18Buy710,429$35.1913.84view
SEIDENBERG BETH CDirector 2016-03-18Buy1,420,858$35.1913.84view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
ETF’s with exposure to TESARO, Inc. : April 28, 2016 Apr 28 2016
TESARO, Inc. breached its 50 day moving average in a Bearish Manner : TSRO-US : April 27, 2016 Apr 27 2016
TESARO Celebrates Oncology Nurses With Premiere of "Heroic Hearts" Documentary at Oncology Nursing... Apr 27 2016
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022... Apr 25 2016
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022... Apr 25 2016
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016 Apr 21 2016
TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016 Apr 21 2016
Coverage initiated on Tesaro by FBR Capital Apr 13 2016
TESARO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Apr 11 2016
[$$] Johnson & Johnson to Develop Tesaro's Drug for Prostate Cancer Apr 06 2016
TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen Apr 06 2016
TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen Apr 06 2016
Tesaro Rises on $85 Million J&J Cancer Drug Licensing Deal Apr 06 2016
TESARO, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 04 2016
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors Apr 04 2016
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors Apr 04 2016
TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License... Mar 29 2016
TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042 Mar 29 2016
TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042 Mar 29 2016
TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License... Mar 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)